Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech and AstraZeneca Sign New Three-Year Collaboration

publication date: Jun 10, 2008

WuXi PharmaTech has extended its collaboration with AstraZeneca for an additional three years. The first collaboration between the two companies, a $14 million two-year agreement begun in 2006, was very successful. During the last two years, using its high throughput screening capability, WuXi delivered over 100,000 compounds to AstraZeneca, two months ahead of schedule. The new agreement calls for WuXi to, once again, synthesize compounds, following designs indicated by AstraZeneca. More details...

Stock Symbols: (NYSE: WX) (NYSE: AZN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital